Pliant Therapeutics appoints two new independent directors, expands board to nine

PLIANT THERAPEUTICS, INC.

Board size increased from 7 to 9; Robert Iannone, M.D. and Flavia Borellini, Ph.D. appointed as Class I and Class II directors respectively.
Iannone joins R&D Committee; Borellini appointed chair of R&D Committee.
Each new director receives annual retainer of $40,000, plus committee fees; each granted option for 60,000 shares vesting over 3 years.
Both directors determined independent under SEC and Nasdaq rules; no material transactions with company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.